The Truth About Biotech Investor Relations

I worked at an investor relations advisory firm early in my career, one where the managing director I worked under later went on to chair a large middle-market dealmaking bank in healthcare coverage. I've stayed close to biotech IR and biotech IB ever since, and I still advise biotech and health tech leaders today. I want to correct a stereotype I think is genuinely wrong.

The "outsourced consultant" stereotype

The first thing most people assume about biotech IR advisory is that it's outsourced work, something a company pays for because it has to, not because it matters. I understand why that stereotype exists. But it's wrong, and I think it undersells one of the more interesting seats in this entire industry. IR sits at the exact intersection where a company's internal ego, its communication style, and the buy side's actual perception of the business all collide in real time. That is not busywork. That is a genuinely difficult communication and judgment problem, every single day.

Reading sentiment, not just data

We built real relationships with top funds, names like Point72, Perceptive Advisors, and Citadel, and what I came to understand is that they used us specifically to read the sentiment of a company, to actually understand what a biotech company is beyond the headline Phase 1 or Phase 2 data. Statistical significance and hitting your primary endpoint p-values obviously matters. But it is not everything. A lot of biotech CEOs face a genuinely difficult predicament with bad trial results: disclose the information bluntly and honestly, or find a way to frame a bad result so it reads as more normal than it is. Neither approach is inherently wrong. The actual job of IR is making sure the communication between the company and the buy side and equity research stays honest and functional regardless of which style a given CEO leans toward.

Why every CEO communicates differently

Every CEO I worked with handled bad news differently, and part of IR's job is understanding which style you're working with and adjusting how you communicate the company's story to the market accordingly. That's a genuinely underrated skill. It has nothing to do with modeling and everything to do with reading people accurately under real pressure, then translating that into something the buy side can actually use.

The senior strategist who told me you don't need a PhD

Along the way, I built real relationships with equity research analysts, and they were genuinely impressive, several with PhDs in biotech or a related health science, and far more technically knowledgeable than I was on the pure science. But one senior equity research strategist at a top-tier bank told me something that stuck with me for years: "Jus, you don't even need a PhD to analyze biotech stocks." His point wasn't that the science doesn't matter. It was that a lot of what looks like impenetrable expertise from the outside is actually a learnable playbook, and the real edge is being able to run that playbook quickly and do real diligence on the people running the company, not just the molecule.

0 to 100x, and 200x to delisted

I've had a genuinely rare vantage point on this: I've watched biotech stocks run from essentially nothing to 100x, and I've watched others run up 200x and then collapse all the way back to zero and get delisted. Over time you learn to see the actual indicators and the actions that precede each outcome. The buy side investors who were genuinely sharp saw those signals and got out ahead of the collapse. The ones who were relying on surface-level data, headline results without digging into what was actually happening underneath, tended to hold on too long, well past where their own stop-loss logic should have told them to exit.

Shareholder-base analysis beyond the 13F

A big part of the actual work was 13F-based shareholder analysis, using tools like Nasdaq IR Intelligence and other emerging platforms at the time to identify the real shareholder base beyond what 13F filings alone disclose. That matters because passive shareholders and active shareholders behave completely differently. If you can identify a passive holder and give them a genuine reason to engage actively with the story, they can become real advocates for the stock, not just a name sitting quietly in a filing. That conversion, passive to active, was some of the most interesting and highest-leverage work in the entire job.

Who IR actually talks to

IR isn't just talking to hedge funds. I spoke directly with family offices and retirement systems as well. I remember a conversation with a senior relationship manager at a retirement system who told me they hold dinners specifically to discuss rising companies, real due diligence happening in a genuinely informal setting. Family offices and hedge funds alike need to actually understand a company's shareholder base and its story, not just its data, before they commit real capital. That range of audience, from a PhD-holding equity research analyst to a retirement-system relationship manager at a dinner, is part of what makes this job more interesting than the outsourced-consultant stereotype gives it credit for.

What this actually means for you

If you're considering biotech IR, or you're in equity research or on the buy side trying to get a real read on a biotech name, the honest version is this: the trial data matters, but it is not the whole picture. How a CEO chooses to communicate a difficult result, who actually holds the stock and whether they're engaged or passive, and whether you can read the real signals behind the headline numbers, those are the things that separate the investors who got out at 200x from the ones who rode a stock to delisting. You don't need a PhD to do this work well. You need to actually build the relationships and do the diligence that the surface-level data will never show you.